Dublin, Aug. 11, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Bispecific Antibody Market & Clinical Pipeline Insight 2020" drug pipelines to their offering.

The pipeline of bispecific antibodies seems to be extremely rich with more than 100 proposed drugs in trials with most of them being in their Preclinical trials. Most of these drugs are propagated to enter the market in the coming 5 to 6 years, occupying a huge segment of health market. The phase is stipulated to swirl the medical world as this will for sure lead to more investments in this direction. The major challenges associated are the monetary restrictions for both the manufacturers as well as the consumers.

Everything novel in medical sector comes with a huge price tag and this was proved by extensively costly therapy of Blinatumomab, which costed $178,000 per two-cycles making it unachievable for the common patients. Other associated challenges include stringent regulatory guidelines, conduction of clinical trials and long duration of research associated.

This report extensively covers the major events from the infancy to the present status of the Bispecific antibodies. It gives a purposeful outlook of the bright future of this wonder molecule which is sure to establish its niche in the coming years; as the abnormalities it is proposed to deal with along with the ways to mitigate them is proportionately too high to be ignored.

Global Bispecific Antibody Market & Clinical Pipeline Insight 2020 Report Highlights:

- Overview of Bispecific Antibody
- Mechanism of Action of Bispecific Antibody
- Design & Engineering of Bispecific Antibodies
- Applications of Bispecific Antibodies
- Global Bispecific Antibodies Clinical Pipeline by Company, Indication & Phase
- Global Bispecific Antibodies Clinical Pipeline: 123 Bispecific Antibodies
- Marketed Bispecific Antibodies: Blinatumomab (Blincyto) & Catumaxomab (Removab)

Key Topics Covered:

1. History of Monoclonal Antibodies

2. Overview of Bispecific Monoclonal Antibody

3. Mechanism of Action of Bispecific Antibody
3.1 Trifunctional Antibody: Catumaxomab (Removab®)
3.2 Blinatumomab

4. The Design & Engineering of Bispecific Antibodies
4.1 The Design & Engineering of IgG like Bispecific Antibodies
4.1.1 Quadroma (Hybrid Hydromas) Approach
4.1.2 Knobs Into Holes Approach
4.1.3 CrossMab Approach
4.1.4 Dual-Variable-Domain Immunoglobulin Approach
4.2 Small Bispecific Antibodies
4.2.1 Bispecific Diabodies
4.2.2 Bispecific T-Cell Engager Antibodies (BiTEs)

5. Advantage of Bispecific Antibodies upon Monospecific Monoclonal Antibodies

6. Applications of Bispecific Antibodies
6.1 BsMAb for Diagnosis of Infectious Diseases
6.1.1 Diagnosis of Bacterial Infections
6.1.2 Diagnosis of Viral Infections
6.2 BsMAb for Cancer Diagnostic
6.3 BsAbs Blocking Signaling Pathways
6.4 BsAbs Targeting Tumor Angiogenesis
6.5 Specific Delivery of Effector Compounds to Targets
6.6 Bispecific Antibodies & Gene Therapy

7. Global Bispecific Antibody Market Overview
7.1 Current Market Scenario
7.1.1 Catumaxomab (Removab)
7.1.2 Blinatumomab
7.1.3 Duligotumab
7.1.4 SAR 156597
7.2 Global Bispecific Antibodies Clinical Pipeline Overview

8. Global Bispecific Antibody Market Dynamics
8.1 Favorable Market Parameters
8.1.1 Target Patient Base
8.1.2 Severity Of The Disease
8.1.3 Unavailability Of Completely Curing Drugs
8.1.4 Side Effects of the Existing Drugs
8.1.5 Specificity of Monoclonal Antibodies in Targeting Cancer Cells
8.2 Commercialization Challenges
8.2.1 Stringent Regulatory Guidelines
8.2.2 Long Duration of Research & Development
8.2.3 Clinical Trial Timeline
8.2.4 High Cost for Research & Development

9. Global Bispecific Antibody Market Future Prospects

10. Global Bispecific Antibodies Clinical Pipeline by Company, Indication & Phase
10.1 Research
10.2 Preclinical
10.3 Phase-I
10.4 Phase-I/II
10.5 Phase-II
10.6 Phase-III

11. Marketed Bispecific Antibodies Clinical Insight
11.1 Blinatumomab (Blincyto)
11.2 Catumaxomab (Removab)

12. Discontinued & Suspended Bispecific Antibodies in Clinical Pipeline by Company, Indication & Phase
12.1 Discontinued
12.2 No Development Reported

13. Competitive Landscape
13.1 Ablynx
13.2 Adimab
13.3 Affimed Therapeutics
13.4 Amgen
13.5 AstraZeneca (MedImmune)
13.6 Chugai Pharmaceutical
13.7 Eli Lilly
13.8 EMD Serono
13.9 Emergent BioSolutions
13.10 Genentech
13.11 Genmab
13.12 Immunomedics
13.13 Jounce Therapeutics
13.14 MacroGenics
13.15 Merus
13.16 Neovii Biotech
13.17 NovImmune SA
13.18 OncoMed Pharmaceuticals
13.19 Pieris
13.20 Regeneron Pharmaceuticals
13.21 Roche
13.22 Sanofi

For more information visit http://www.researchandmarkets.com/research/758qpr/global_bispecific

CONTACT: Research and Markets
         Laura Wood, Senior Manager

         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716